First-line l-asparaginase-based chemotherapy plus radiotherapy is active in stage i/ii extranodal nk/t-cell lymphoma: results from peking university cancer hospital
Y. Song,J. Jia,M. Wu,X. Leng,N. Lin,Y. Xie,W. Zheng,X. Wang,L. Ping,M. Tu,Z. Ying,C. Zhang,W. Liu,L. Deng,J. Zhu
DOI: https://doi.org/10.1002/hon.2437_113
IF: 4.85
2017-01-01
Hematological Oncology
Abstract:Introduction: Although most patients diagnosed with extranodal nasal-type natural killer/T-cell lymphoma (NKTCL) have localized disease, the survival outcomes of radiotherapy alone or conventional doxorubicin-based chemotherapy were considered unsatisfactory. This study is retrospectively to investigate the effects and potential survival benefits of L-asparaginase-based chemotherapy and locoregional radiotherapy as first-line treatments in early-staged NKTCL patients. Methods: From April 2001 to July 2016, a total of 196 pts diagnosed as stage I/II NKTCL were treated in Peking University Cancer Hospital. All patients were confirmed by immunohistochemistry staining according to WHO Classification criteria. Median age was 43 years (range 12 to 81) with 74.0% males (n = 145). 84 (42.9%) cases presented with B symptoms, and 17 (8.72%) cases with IPI score ≥ 2.Among of them, 58 (29.6%) received chemotherapy alone, and 138 (70.4%) received chemotherapy combined with concurrent or sequential locoregional radiotherapy (dosage from 50 to 56Gy) as first-line treatment. Chemo-regimens included CHOP-like, CHOP-L (CHOP + L-asparaginase), COEP-L (etoposide instead of doxorubicin), LOP (vincristine, prednisolone, L-asparaginase) or GDP-L (gemcitabine, cisplatin, dexamethasone +L-asparaginase). Results: After a median follow-up period of 109 months (range, 4-187 months), clinical outcomes of 173 evaluable patients were analyzed. For patients received chemotherapy alone, the complete response (CR) rates of CHOP-like, CHOP-L and COEP-L regimen were 21.1%, 66.7%, 60%, respectively; the overall response rates (ORR) were 47.4%, 86.7%, 60%, respectively. For patients received radiochemotherapy, the CR rates of CHOP-like + RT, CHOP-L + RT and COEP-L + RT were 61.9%, 91.1%, 86.9%, respectively; the ORR were 66.7%, 93.3%, 96.7%, respectively. The one-year progression-free survival (PFS) was only 54.7% in CHOP-like group, while the median PFS in CHOP-L and COEP-L groups had not reached. The PFS were significantly superior in CHOP-L and COEP-L groups as compared to CHOP-like group (p < 0.001). But the PFS showed no apparent difference between CHOP-L and COEP-L groups (p = 0.644). For patients received chemotherapy alone, the one-year PFS was only 57.1%. However, with the addition of locoregional radiotherapy, the one-year PFS improved to 88.8% (p = 0.002). Keywords: L-asparaginase; peripheral T-cell lymphomas (PTCL).